SEC Filing Summary for Barry Hassett

Barry Hassett, Chief Commercial Officer at BioStem Technologies, Inc., reported a transaction on September 9, 2026. He acquired 500 shares of Common Stock with a transaction price of $0.00. Following this transaction, Hassett owns 5003 shares of Common Stock directly. Additionally, Hassett disposed of 500 Restricted Stock Units. These units represent a contingent right to receive one share of the issuer's common stock upon vesting, which occurs in quarterly installments over four years from the grant date of December 9, 2024. After this disposal, Hassett holds 4497 Restricted Stock Units. The filing also details various stock options and restricted stock units held by Hassett, with vesting schedules and underlying common stock information provided in accompanying footnotes.